Pociredir Clinical Trials (2026): 3 Studies for Sickle Cell Disease & Sickle Cell Anemia
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
3 Pociredir clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Sickle Cell Disease & Sickle Cell Anemia) and 108 total planned enrollment. 1 Pociredir clinical trial is actively recruiting. Most recent activity: NCT07401823 (Jul 2030).
Pociredir clinical trials at a glance: phase × recruitment status
| Phase | enrolling by invitation | completed | terminated | Total |
|---|---|---|---|---|
| P1 | 1 | 1 | 2 | |
| P2 | 1 | 1 |
Recruiting Pociredir clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07401823 | Open-Label Extension Study to Pioneer Study 6058-SCD-101 | P2 | Sickle Cell Disease | 50 | Mar 2026 |
Terminated and withdrawn Pociredir trials (1)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT07431398terminatedSingle-dose Pharmacokinetics of Pociredir in Participants With Sickle Cell Disease
All Pociredir trials (3)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07401823 | Open-Label Extension Study to Pioneer Study 6058-SCD-101 | P2 | enrolling by invitation | 50 | Fulcrum Therapeutics | Mar 2026 | |
| NCT07431398 | Single-dose Pharmacokinetics of Pociredir in Participants With Sickle Cell Disease | P1 | terminated | 13 | Fulcrum Therapeutics | Dec 2025 | |
| NCT05169580 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pociredir | P1 | completed | 45 | Fulcrum Therapeutics | Dec 2021 |
Pociredir clinical trials: frequently asked questions
- How many Pociredir clinical trials are there?
- 3 Pociredir clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants. 1 is marked completed.
- Are Pociredir clinical trials recruiting in 2026?
- Yes — 1 Pociredir trial is actively recruiting in 2026. See the recruiting trials and the per-state site list further down this page.
- What conditions is Pociredir being studied for?
- Pociredir is being studied for Sickle Cell Disease, Sickle Cell Anemia. The trials are grouped by indication on this page.
- What phase is Pociredir in?
- Pociredir clinical trials span 1 Phase 2, 2 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Pociredir clinical trials?
- The lead sponsor across the most Pociredir trials is Fulcrum Therapeutics. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Pocirediras an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: